Menopause & Blood Clot Risk: Hormonal Changes, Risk Factors & Prevention

Menopause and Increased Thrombotic Risk: What Women Should Know

Yes, menopause increases venous thromboembolism (VTE) risk. The decline in endogenous estrogen alters hemostatic balance, and age-related comorbidities compound risk.

Mechanisms

  • Estrogen decline: ↓ Antithrombin, ↓ Protein S, ↑ Fibrinogen, ↑ Factor VIII, ↓ Fibrinolysis
  • Prothrombotic shift: Net hypercoagulable state
  • Hormone Therapy (HT): Oral estrogen ↑ VTE 2–4×; Transdermal estrogen → minimal/no increase

Risk Factors During Menopause

  • Age: VTE incidence rises exponentially after 50
  • Obesity (BMI ≥30): 2–3× risk; adipose = prothrombotic
  • Smoking: Endothelial damage + hypercoagulability
  • Immobility/surgery: Major transient risks
  • Medical conditions: Cancer, heart failure, IBD, nephrotic syndrome, antiphospholipid syndrome
  • Genetics: Factor V Leiden, Prothrombin G20210A, family history
  • Oral HT: Avoid in high-risk women; transdermal preferred if HT indicated

VTE Symptoms (DVT / PE)

  • DVT: Unilateral leg swelling, pain, warmth, erythema, cord-like vein
  • PE: Sudden dyspnea, pleuritic chest pain, tachycardia, syncope, hemoptysis

Prevention & Action

  • Know your risk factors; discuss with clinician
  • If HT needed: transdermal estrogen (patch/gel) + micronized progesterone
  • Maintain healthy weight, quit smoking, stay active
  • Hydration, compression stockings for travel/surgery
  • Seek immediate care for DVT/PE symptoms

Menopause is a risk amplifier. Proactive assessment and transdermal HT (if used) mitigate thrombotic risk.

Women's Health - Related Articles